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Exosomes (or extracellular vesicles) are rapidly gaining momentum as a novel type of regenerative medicine. 
Exosomes are nano-vesicles in the size range of 20-150nm that are secreted by mammalian cell types 
(including stem cells). They can induce potent biological functions in surrounding target cells to induce effects 
that mimic those of the producing cell. These functions can be regenerative, immunomodulatory, anti-scarring 
and even anti-cancer depending on the state of the producer cell. Consequently, there is enormous potential to 
develop a range of function-specific products across a wide variety of indications similar to macromolecular 
blockbusters, but which extend beyond symptom management to produce curative outcomes. However, current 
methods for purifying exosomes have been based on technologies grandfathered in from the viral industry which 
are not suitable for large scale, high purity production but are robust enough to perform preliminary 
characterisation of the exosome population composition. 
 
The aim of this study was to develop a new platform technology/process for purification at commercially relevant 
scales to acceptable regulatory standards. A further aim of this work is to create processes which operate 
orthogonally to the commonly used exosome recovery steps which are predominantly physically based.  
 
A commercial cell line that is in clinical development was 
used to generate exosomes. A wide variety of 
acceptance criteria were established (including particle 
concentration/size distributions, particle:protein ratios, 
host cell DNA/RNA clearance and exosomal specific 
markers such as CD63 and CD81) to ensure quality-
driven process development that is scalable and removes 
cell-culture associated impurities. The monolithic options 
established in this project to date have shown that 
exosome material recovered via batch tangential flow 
filtration can be efficiently captured and recovered from 
both columns whilst removing key process contaminants 
and maintaining a product that retains both identity and 
potency (Figure 1). 
 
